脆弱X症候群（FXS）治療の世界市場レポート 2025年

脆弱X症候群FXS治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で28億1,000万米ドルに成長します。予測期間の成長は、標的治療に対する需要の増加、遺伝子治療への注目の高まり、希少遺伝性疾患に対する認識の高まり、診察における遠隔医療の採用拡大、希少疾患治療に対する保険適用の拡大などに起因すると考えられます。この間の主な動向としては、遺伝子検査の技術進歩、遺伝子編集療法の進歩、研究開発投資の増加、個別化治療法の革新、行動療法アプローチの改善などが挙げられます。

希少疾患に対する政府の取り組みと資金援助が、近い将来の脆弱X症候群（FXS）治療市場の拡大を牽引すると予想されます。希少疾患は、人口のごく一部が罹患する病態であり、多くの場合、慢性的、進行性で、生命を脅かす可能性があります。希少疾患の特定が増加した背景には、遺伝子検査、画像診断、データ分析における診断能力の向上により、以前は発見されなかった、あるいは誤診されていた疾患の診断精度が大幅に向上したことがあります。脆弱X症候群（FXS）治療は、専門的な治療や早期介入の必要性を強調することで、政府の資金援助の重要性を強調しています。例えば、2024年2月、英国議会の下院図書館は、英国全土の11の研究ノードと中央調整ハブを特徴とする全国希少疾患研究プラットフォームを構築するために、政府が1,400万ポンド（1,730万米ドル）を拠出することを報告しました。したがって、希少疾患に対する政府の投資はFXS治療市場の成長を加速させています。

脆弱X症候群（FXS）治療市場の主な企業は、根本的な神経機能障害に対処し、治療成績を向上させるために、カルシウム活性化カリウム（BK）チャネル活性化剤などの革新的な治療法の開発を優先しています。BKチャネル活性化剤は、細胞の興奮性と神経伝達物質の放出を制御するカリウムチャネルの機能を高める。例えば、2025年1月、米国のバイオテクノロジー企業であるスピノジェニックス社は、FXS治療を目的としたBKチャネル活性化剤SPG601について、米国食品医薬品局（FDA）からファスト・トラック指定を受けた。この指定により、臨床開発と規制当局による承認が加速され、シナプス機能障害に対処するためにデザインされたこの新しい治療オプションが患者により身近なものとなります。また、有効なFXS治療に対する緊急のニーズと、主要な神経学的メカニズムを標的とすることで認知・行動症状を緩和するSPG601の可能性を反映しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の脆弱X症候群（FXS）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脆弱X症候群（FXS）治療市場：成長率分析
• 世界の脆弱X症候群（FXS）治療市場の実績：規模と成長、2019年～2024年
• 世界の脆弱X症候群（FXS）治療市場の予測：規模と成長,、2024年～2029年、2034年
• 世界の脆弱X症候群（FXS）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脆弱X症候群（FXS）治療市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 薬物治療
• 心理療法
• 教育と訓練
• 世界の脆弱X症候群（FXS）治療市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 注射剤
• 局所
• 世界の脆弱X症候群（FXS）治療市場：関連疾患別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 脆弱X症候群
• 脆弱X症候群1型（FMR1）関連原発性卵巣機能不全
• 脆弱X連鎖性脆弱E（XE）症候群
• レンペニング症候群
• その他の関連疾患
• 世界の脆弱X症候群（FXS）治療市場：患者の年齢層別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 子供
• 大人
• 高齢者
• 世界の脆弱X症候群（FXS）治療市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の脆弱X症候群（FXS）治療市場、薬物治療のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 抗うつ薬
• 抗精神病薬
• 覚醒剤
• 抗けいれん薬
• 抗不安薬
• mGluR5拮抗薬（代謝型グルタミン酸受容体5拮抗薬）
• GABA作動薬（γ-アミノ酪酸作動薬）
• 世界の脆弱X症候群（FXS）治療市場、心理療法の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 認知行動療法（CBT）
• 家族療法
• ソーシャルスキルトレーニング
• 作業療法
• 言語療法
• 応用行動分析（ABA）
• 世界の脆弱X症候群（FXS）治療市場、教育と訓練の種類別のサブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 特別教育プログラム
• 個別教育プログラム（IEP）
• 親のトレーニングとサポート
• 行動介入計画
• スキル構築ワークショップ
• インクルーシブな教室戦略

第7章 地域別・国別分析

• 世界の脆弱X症候群（FXS）治療市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の脆弱X症候群（FXS）治療市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脆弱X症候群（FXS）治療市場：競合情勢
• 脆弱X症候群（FXS）治療市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Shionogi & Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Marinus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Healx Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Neuren Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Vincerx Pharma Inc.
• Fulcrum Therapeutics Inc.
• Neuronascent Inc.
• Autifony Therapeutics Limited
• Quadrant Biosciences Inc.
• Neurolixis Inc.
• Taysha Gene Therapies Inc.
• Ovid Therapeutics Inc.
• Spinogenix Inc.
• Epigen Biosciences Inc.
• Confluence Pharmaceuticals Inc.
• Actinogen Medical Limited
• Sentinel Oncology Limited
• Anavex Life Sciences Corp.
• FRAXA Research Foundation Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脆弱X症候群（FXS）治療市場2029年：新たな機会を提供する国
• 脆弱X症候群（FXS）治療市場2029年：新たな機会を提供するセグメント
• 脆弱X症候群（FXS）治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Fragile X Syndrome (FXS) treatment encompasses a combination of medical, therapeutic, and educational strategies aimed at managing symptoms and enhancing the quality of life for individuals affected by this genetic disorder, which leads to intellectual disabilities, behavioral challenges, and developmental delays. Common symptoms include developmental delays, difficulties in social interaction and communication, along with distinct physical features such as an elongated face and prominent ears. Treatment for FXS commonly involves pharmaceutical drugs such as antidepressants, antipsychotics, and stimulants to address behavioral concerns.

The primary treatment approaches for FXS include pharmacological interventions, psychotherapy, and educational and training programs. Pharmacological treatment focuses on using medications to manage symptoms such as anxiety, hyperactivity, and mood disorders, targeting specific neurological and behavioral challenges to improve patient well-being. These medications may be delivered orally, via injections, or through topical applications. Related conditions include Fragile X Syndrome, Fragile X Mental Retardation 1 (FMR1)-related primary ovarian insufficiency, Fragile X-linked Fragile E (XE) syndrome, Renpenning syndrome, and other associated disorders. Treatments are applied across all age groups-children, adults, and the elderly and are generally provided in hospitals, specialized clinics, and various healthcare facilities.

The fragile x syndrome (FXS) treatment market research report is one of a series of new reports from The Business Research Company that provides fragile x syndrome (FXS) treatment market statistics, including the fragile x syndrome (FXS) treatment industry global market size, regional shares, competitors with the fragile x syndrome (FXS) treatment market share, detailed fragile x syndrome (FXS) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fragile x syndrome (FXS) treatment industry. This fragile x syndrome (FXS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fragile X syndrome FXS treatment market size has grown strongly in recent years. It will grow from $1.92 billion in 2024 to $2.08 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to heightened awareness of Fragile X Syndrome, a rising prevalence of genetic disorders, increased adoption of early diagnosis and screening practices, expanded government funding for rare disease research, and growing demand for personalized treatment approaches.

The fragile X syndrome FXS treatment market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing demand for targeted therapies, a heightened focus on gene therapies, growing awareness of rare genetic disorders, greater adoption of telemedicine for consultations, and broader insurance coverage for rare disease treatments. Key trends during this period include technological progress in genetic testing, advancements in gene-editing therapies, increased investment in research and development, innovations in personalized treatment methods, and improvements in behavioral therapy approaches.

Government initiatives and funding for rare diseases are expected to drive the expansion of the fragile X syndrome (FXS) treatment market in the near future. Rare diseases are medical conditions that impact a small fraction of the population and are often chronic, progressive, and potentially life-threatening. The rise in the identification of rare diseases can be attributed to enhanced diagnostic capabilities advancements in genetic testing, imaging, and data analysis have significantly improved the accuracy of diagnosing conditions that were previously undetected or misdiagnosed. Fragile X syndrome (FXS) treatment highlights the significance of government funding by underlining the need for specialized therapies and early interventions, which help to raise awareness and channel resources toward expanded research and medical care. For instance, in February 2024, the UK Parliament's House of Commons Library reported a government commitment of £14 million ($17.3 million) to create a national rare disease research platform, featuring 11 research nodes and a central coordinating hub across the UK. Therefore, government investment in rare diseases is accelerating the growth of the FXS treatment market.

Key players in the fragile X syndrome (FXS) treatment market are prioritizing the development of innovative therapies, such as calcium-activated potassium (BK) channel activators, to address underlying neurological dysfunction and improve treatment outcomes. A BK channel activator enhances the function of potassium channels that control cell excitability and neurotransmitter release. For example, in January 2025, Spinogenix Inc., a US-based biotechnology company, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SPG601, a BK channel activator intended for FXS treatment. This designation accelerates clinical development and regulatory approval, bringing this novel therapeutic option designed to address synaptic dysfunction closer to patients. It also reflects the urgent need for effective FXS treatments and the potential of SPG601 to alleviate cognitive and behavioral symptoms by targeting key neurological mechanisms.

In August 2023, Harmony Biosciences Holdings Inc., a US-based commercial-stage pharmaceutical firm, acquired Zynerba Pharmaceuticals for approximately $60 million. This acquisition enables Harmony to diversify its therapeutic offerings and strengthen its pipeline by integrating Zynerba's lead candidate, Zygel a synthetic cannabidiol gel currently in Phase 3 trials for Fragile X syndrome and Phase 2 trials for 22q11.2 deletion syndrome. Zygel has received both orphan drug and FDA Fast Track designations for Fragile X syndrome. Zynerba Pharmaceuticals Inc. is a US-based biopharma company specializing in the development of transdermal cannabinoid treatments for FXS.

Major players in the fragile x syndrome (fxs) treatment market are F. Hoffmann-La Roche Ltd, Shionogi & Co. Ltd., Marinus Pharmaceuticals Inc., Healx Ltd, Neuren Pharmaceuticals Limited, Vincerx Pharma Inc., Fulcrum Therapeutics Inc., Neuronascent Inc., Autifony Therapeutics Limited, Quadrant Biosciences Inc., Neurolixis Inc., Taysha Gene Therapies Inc., Ovid Therapeutics Inc., Spinogenix Inc., Epigen Biosciences Inc., Confluence Pharmaceuticals Inc., Actinogen Medical Limited, Sentinel Oncology Limited, Anavex Life Sciences Corp., FRAXA Research Foundation Inc.

North America was the largest region in the fragile X syndrome FXS treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fragile x syndrome (FXS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fragile x syndrome (FXS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fragile x syndrome (FXS) treatment market consists of sales of genetic testing services, gene therapies, and behavioral intervention program. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fragile X Syndrome (FXS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fragile x syndrome (fxs) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fragile x syndrome (fxs) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fragile x syndrome (fxs) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Pharmacological Treatment; Psychotherapy; Education And Training
• 2) By Route of Administration: Oral; Injectable; Topical
• 3) By Related Disorder: Fragile X Syndrome; Fragile X Mental Retardation 1 (FMR1)-Related Primary Ovarian Insufficiency; Fragile X-linked Fragile E (XE) Syndrome; Renpenning Syndrome; Other Related Disorders
• 4) By Patient Age Group: Children; Adults; Elderly
• 5) By End-User: Hospitals; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Pharmacological Treatment: Antidepressants; Antipsychotics; Stimulants; Anticonvulsants; Anti-Anxiety Medications; mGluR5 Antagonists (Metabotropic Glutamate Receptor 5 Antagonists); GABA Agonists (Gamma-Aminobutyric Acid Agonists)
• 2) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Family Therapy; Social Skills Training; Occupational Therapy; Speech And Language Therapy; Applied Behavior Analysis (ABA)
• 3) By Education And Training: Special Education Programs; Individualized Education Programs (IEPs); Parent Training And Support; Behavioral Intervention Plans; Skill-Building Workshops; Inclusive Classroom Strategies
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Shionogi & Co. Ltd.; Marinus Pharmaceuticals Inc.; Healx Ltd; Neuren Pharmaceuticals Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fragile X Syndrome (FXS) Treatment Market Characteristics

3. Fragile X Syndrome (FXS) Treatment Market Trends And Strategies

4. Fragile X Syndrome (FXS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fragile X Syndrome (FXS) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fragile X Syndrome (FXS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fragile X Syndrome (FXS) Treatment Market Growth Rate Analysis
• 5.4. Global Fragile X Syndrome (FXS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fragile X Syndrome (FXS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fragile X Syndrome (FXS) Treatment Total Addressable Market (TAM)

6. Fragile X Syndrome (FXS) Treatment Market Segmentation

• 6.1. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacological Treatment
• Psychotherapy
• Education And Training
• 6.2. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.3. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fragile X Syndrome
• Fragile X Mental Retardation 1 (FMR1)-Related Primary Ovarian Insufficiency
• Fragile X-linked Fragile E (XE) Syndrome
• Renpenning Syndrome
• Other Related Disorders
• 6.4. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adults
• Elderly
• 6.5. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End Users
• 6.6. Global Fragile X Syndrome (FXS) Treatment Market, Sub-Segmentation Of Pharmacological Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants
• Antipsychotics
• Stimulants
• Anticonvulsants
• Anti-Anxiety Medications
• mGluR5 Antagonists (Metabotropic Glutamate Receptor 5 Antagonists)
• GABA Agonists (Gamma-Aminobutyric Acid Agonists)
• 6.7. Global Fragile X Syndrome (FXS) Treatment Market, Sub-Segmentation Of Psychotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Behavioral Therapy (CBT)
• Family Therapy
• Social Skills Training
• Occupational Therapy
• Speech And Language Therapy
• Applied Behavior Analysis (ABA)
• 6.8. Global Fragile X Syndrome (FXS) Treatment Market, Sub-Segmentation Of Education And Training, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Special Education Programs
• Individualized Education Programs (IEPs)
• Parent Training And Support
• Behavioral Intervention Plans
• Skill-Building Workshops
• Inclusive Classroom Strategies

7. Fragile X Syndrome (FXS) Treatment Market Regional And Country Analysis

• 7.1. Global Fragile X Syndrome (FXS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fragile X Syndrome (FXS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market

• 8.1. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fragile X Syndrome (FXS) Treatment Market

• 9.1. China Fragile X Syndrome (FXS) Treatment Market Overview
• 9.2. China Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fragile X Syndrome (FXS) Treatment Market

• 10.1. India Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fragile X Syndrome (FXS) Treatment Market

• 11.1. Japan Fragile X Syndrome (FXS) Treatment Market Overview
• 11.2. Japan Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fragile X Syndrome (FXS) Treatment Market

• 12.1. Australia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fragile X Syndrome (FXS) Treatment Market

• 13.1. Indonesia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fragile X Syndrome (FXS) Treatment Market

• 14.1. South Korea Fragile X Syndrome (FXS) Treatment Market Overview
• 14.2. South Korea Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fragile X Syndrome (FXS) Treatment Market

• 15.1. Western Europe Fragile X Syndrome (FXS) Treatment Market Overview
• 15.2. Western Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fragile X Syndrome (FXS) Treatment Market

• 16.1. UK Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fragile X Syndrome (FXS) Treatment Market

• 17.1. Germany Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fragile X Syndrome (FXS) Treatment Market

• 18.1. France Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fragile X Syndrome (FXS) Treatment Market

• 19.1. Italy Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fragile X Syndrome (FXS) Treatment Market

• 20.1. Spain Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fragile X Syndrome (FXS) Treatment Market

• 21.1. Eastern Europe Fragile X Syndrome (FXS) Treatment Market Overview
• 21.2. Eastern Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fragile X Syndrome (FXS) Treatment Market

• 22.1. Russia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fragile X Syndrome (FXS) Treatment Market

• 23.1. North America Fragile X Syndrome (FXS) Treatment Market Overview
• 23.2. North America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fragile X Syndrome (FXS) Treatment Market

• 24.1. USA Fragile X Syndrome (FXS) Treatment Market Overview
• 24.2. USA Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fragile X Syndrome (FXS) Treatment Market

• 25.1. Canada Fragile X Syndrome (FXS) Treatment Market Overview
• 25.2. Canada Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fragile X Syndrome (FXS) Treatment Market

• 26.1. South America Fragile X Syndrome (FXS) Treatment Market Overview
• 26.2. South America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fragile X Syndrome (FXS) Treatment Market

• 27.1. Brazil Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fragile X Syndrome (FXS) Treatment Market

• 28.1. Middle East Fragile X Syndrome (FXS) Treatment Market Overview
• 28.2. Middle East Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fragile X Syndrome (FXS) Treatment Market

• 29.1. Africa Fragile X Syndrome (FXS) Treatment Market Overview
• 29.2. Africa Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fragile X Syndrome (FXS) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Fragile X Syndrome (FXS) Treatment Market Competitive Landscape
• 30.2. Fragile X Syndrome (FXS) Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Shionogi & Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Marinus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Healx Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Neuren Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis

31. Fragile X Syndrome (FXS) Treatment Market Other Major And Innovative Companies

• 31.1. Vincerx Pharma Inc.
• 31.2. Fulcrum Therapeutics Inc.
• 31.3. Neuronascent Inc.
• 31.4. Autifony Therapeutics Limited
• 31.5. Quadrant Biosciences Inc.
• 31.6. Neurolixis Inc.
• 31.7. Taysha Gene Therapies Inc.
• 31.8. Ovid Therapeutics Inc.
• 31.9. Spinogenix Inc.
• 31.10. Epigen Biosciences Inc.
• 31.11. Confluence Pharmaceuticals Inc.
• 31.12. Actinogen Medical Limited
• 31.13. Sentinel Oncology Limited
• 31.14. Anavex Life Sciences Corp.
• 31.15. FRAXA Research Foundation Inc.

32. Global Fragile X Syndrome (FXS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fragile X Syndrome (FXS) Treatment Market

34. Recent Developments In The Fragile X Syndrome (FXS) Treatment Market

35. Fragile X Syndrome (FXS) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Fragile X Syndrome (FXS) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fragile X Syndrome (FXS) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fragile X Syndrome (FXS) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer